Literature DB >> 9764958

Prescription-event monitoring--recent progress and future horizons.

R D Mann1.   

Abstract

Mesh：

Year:  1998        PMID： 9764958      PMCID： PMC1873686          DOI： 10.1046/j.1365-2125.1998.00774.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

1.  Prescription-event monitoring (PEM) in 1996-a method of non-interventional observational cohort pharmacovigilance.

Authors:  R D Mann; L V Wilton; G L Pearce; F J Mackay; N R Dunn
Journal:  Pharmacoepidemiol Drug Saf       Date:  1997-10       Impact factor: 2.890

2.  Study of United Kingdom product licence applications containing new active substances, 1987-9.

Authors:  M D Rawlins; D B Jefferys
Journal:  BMJ       Date:  1991-01-26

3.  Safety of long-term lamotrigine in epilepsy.

Authors:  F J Mackay; L V Wilton; G L Pearce; S N Freemantle; R D Mann
Journal:  Epilepsia       Date:  1997-08       Impact factor: 5.864

4.  Severe persistent visual field constriction associated with vigabatrin.

Authors:  T Eke; J F Talbot; M C Lawden
Journal:  BMJ       Date:  1997-01-18

5.  The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients.

Authors:  L Wilton; G Pearce; E Edet; S Freemantle; M D Stephens; R D Mann
Journal:  Br J Urol       Date:  1996-09

6.  Myocardial infarction and oral contraceptives, a retrospective case control study in England and Scotland ('MICA' Study).

Authors:  N R Dunn; M Thorogood; L de Caestecker; R D Mann
Journal:  Pharmacoepidemiol Drug Saf       Date:  1997-07       Impact factor: 2.890
  6 in total
  36 in total

1.  Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England.

Authors:  S A Shakir; L V Wilton; A Boshier; D Layton; E Heeley
Journal:  BMJ       Date:  2001-03-17

2.  Visual field defect associated with vigabatrin: observational cohort study.

Authors:  L V Wilton; M D Stephens; R D Mann
Journal:  BMJ       Date:  1999-10-30

Review 3.  Pharmacovigilance in perspective.

Authors:  R H Meyboom; A C Egberts; F W Gribnau; Y A Hekster
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

4.  Automated signal generation in prescription-event monitoring.

Authors:  Emma Heeley; Lynda V Wilton; Saad A W Shakir
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 5.  Application of data mining techniques in pharmacovigilance.

Authors:  Andrew M Wilson; Lehana Thabane; Anne Holbrook
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

Review 6.  The potential of UK clinical databases in enhancing paediatric medication research.

Authors:  Ian C K Wong; Macey L Murray
Journal:  Br J Clin Pharmacol       Date:  2005-06       Impact factor: 4.335

7.  Drug safety without borders: concerns about bupropion.

Authors:  Barbara Mintzes; Ken Bassett; James M Wright
Journal:  CMAJ       Date:  2002-09-03       Impact factor: 8.262

8.  Randomized controlled trials and assessment of drug safety.

Authors:  David W J Clark; David M Coulter; Frank M C Besag
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

9.  Pharmacovigilance study of alendronate in England.

Authors:  Pipasha N Biswas; Lynda V Wilton; Saad A W Shakir
Journal:  Osteoporos Int       Date:  2003-04-23       Impact factor: 4.507

10.  The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11 541 patients in England.

Authors:  Lynda V Wilton; Cheryl Key; Saad A W Shakir
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.